Pharma BD Deal Intelligence
Merck will acquire privately held Peloton for $1.05 billion in cash and another $1.15 billion contingent on certain commercialization goals, for a total…
FDA approved Welireg for advanced PPGL (LITESPARK-015), third indication after VHL and RCC.
Merck today announced it has entered into a definitive agreement to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company focused on the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Merck acquired privately held Peloton Therapeutics for up to $2.2 billion ($1.05 billion upfront plus $1.15 billion in milestones), gaining PT2977 (belzutifan/Welireg), a novel oral HIF-2α inhibitor in late-stage development for renal cell carcinoma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Peloton Therapeutics Inc. (this deal) | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2019 deals · Merck & Co. Inc. deals · Oncology deals